Markets / Mutual funds / Sectoral / Thematic

Nippon India Pharma Fund - Regular Plan - Growth

NAVs of 8 Nov 2026

Nippon India Mutual Fund · Equity fund · Regular plan · Growth

Sectoral / ThematicRegular · GrowthRisk: Very High

NAV · 5 Nov 2026

₹568.9138 ▲ 0.35%

Nippon India Mutual Fund

Fund size₹9,272 crJuly - September 2026

1-month range₹524.86 – 568.91

1 year+9.96%rank 55 of 280

3 years+17.96%a year

5 years+13.72%a year

What the fund does

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.

BenchmarkBSE Healthcare TRI

Launched5 Jun 2004

Fund houseNippon India Mutual Fund

Fund managersSailesh Raj Bhan

NAV history

Returns

1 week

+2.99%avg 4.7%

1 month

+2.04%avg 2.4%

3 months

-0.39%avg -2.1%

6 months

+6.07%avg 2.8%

This year

+11.67%avg 3.0%

1 year

+9.96%avg 2.9% · #55/280

3 years (a year)

+17.96%avg 13.7% · #38/165

5 years (a year)

+13.72%avg 11.7% · #42/122

Bars: this plan; the thin mark is the Sectoral / Thematic average (regular plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.

Monthly returns (%)

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024												+1.8
2025	-7.6	-5.9	+6.5	+2.5	+2.2	+2.7	+2.3	-4.1	-2.0	+2.8	+1.6	-2.0
2026	-4.3	+5.7	-4.9	+5.6	+3.1	+4.5	+2.2	+2.0	-3.6	-0.8	+2.5

Each month's change in NAV (the current month to the latest NAV).

What if you had invested?

Amount (₹) Started

Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.

Portfolio as on 30 Sept 2026

Stocks held3639 lines in all

Top 10 stocks56.4%of the fund

Short positions-0.1%sold through derivatives

Net equity97.2%long stocks and derivatives minus shorts

Where the money is

Equity 97.3%Cash & others 2.7%Short -0.1%

Sectors (stocks held)

Pharmaceuticals & Biotechnology

74.0%

Healthcare Services

20.3%

Retailing

2.5%

Healthcare Equipment & Supplies

0.5%

Changes since 31 Aug 2026

Share of fund	30 Sept 2026	31 Aug 2026	Change
Stocks held	97.3%	98.0%	-0.68
Short positions	-0.1%	-0.1%	0.00
Cash & others	2.7%	2.0%	+0.68
Top 10 stocks	56.4%	56.8%	-0.43
Number of stocks	36	36	0

Bought more 2

Dr. Reddy's Laboratories Limited+0.52
Mankind Pharma Limited+0.29

Cut back 3

Sun Pharmaceutical Industries Limited-0.66
Lupin Limited-0.26
Apollo Hospitals Enterprise Limited-0.26

Change is in percentage points. Bought more and cut back list stocks whose share of the fund moved by at least 0.25 points. A share can also move because the price changed, not only because the fund traded.

Stocks held 36

Holding	Sector / type	% of fund
Sun Pharmaceutical Industries Limited INE044A01036	Pharmaceuticals & Biotechnology	11.71%
Divi's Laboratories Limited INE361B01024	Pharmaceuticals & Biotechnology	7.10%
Lupin Limited INE326A01037	Pharmaceuticals & Biotechnology	6.17%
Cipla Limited INE059A01026	Pharmaceuticals & Biotechnology	6.01%
Dr. Reddy's Laboratories Limited INE089A01031	Pharmaceuticals & Biotechnology	5.45%
Apollo Hospitals Enterprise Limited INE437A01024	Healthcare Services	4.89%
Mankind Pharma Limited INE634S01028	Pharmaceuticals & Biotechnology	4.38%
Sai Life Sciences Limited INE570L01029	Pharmaceuticals & Biotechnology	3.92%
Ajanta Pharma Limited INE031B01049	Pharmaceuticals & Biotechnology	3.61%
GlaxoSmithKline Pharmaceuticals Limited INE159A01016	Pharmaceuticals & Biotechnology	3.11%
IPCA Laboratories Limited INE571A01038	Pharmaceuticals & Biotechnology	2.87%
Max Healthcare Institute Limited INE027H01010	Healthcare Services	2.70%
Vijaya Diagnostic Centre Limited INE043W01024	Healthcare Services	2.62%
Gland Pharma Limited INE068V01023	Pharmaceuticals & Biotechnology	2.53%
MedPlus Health Services Limited INE804L01022	Retailing	2.53%
Abbott India Limited INE358A01014	Pharmaceuticals & Biotechnology	2.32%
Thyrocare Technologies Limited INE594H01019	Healthcare Services	2.24%
Piramal Pharma Limited INE0DK501011	Pharmaceuticals & Biotechnology	2.24%
Dr. Lal Path Labs Limited INE600L01024	Healthcare Services	2.17%
Alkem Laboratories Limited INE540L01014	Pharmaceuticals & Biotechnology	1.82%
Aurobindo Pharma Limited INE406A01037	Pharmaceuticals & Biotechnology	1.65%
Narayana Hrudayalaya Limited INE410P01011	Healthcare Services	1.61%
Suraksha Diagnostic Limited INE877V01027	Healthcare Services	1.51%
Syngene International Limited INE398R01022	Healthcare Services	1.40%
Emcure Pharmaceuticals Limited INE168P01015	Pharmaceuticals & Biotechnology	1.36%
Pfizer Limited INE182A01018	Pharmaceuticals & Biotechnology	1.35%
Akums Drugs and Pharmaceuticals Limited INE09XN01023	Pharmaceuticals & Biotechnology	1.21%
Anthem Biosciences Limited INE0CZ201020	Pharmaceuticals & Biotechnology	1.19%
Fortis Healthcare Limited INE061F01013	Healthcare Services	1.13%
Biocon Limited INE376G01013	Pharmaceuticals & Biotechnology	1.01%
Sanofi India Limited INE058A01010	Pharmaceuticals & Biotechnology	1.00%
Sanofi Consumer Healthcare India Limited INE0UOS01011	Pharmaceuticals & Biotechnology	0.89%
Molbio Diagnostics Limited INE869T01028	Healthcare Equipment & Supplies	0.54%
Indoco Remedies Limited INE873D01024	Pharmaceuticals & Biotechnology	0.48%
AstraZeneca Pharma India Limited INE203A01020	Pharmaceuticals & Biotechnology	0.42%
Concord Biotech Limited INE338H01029	Pharmaceuticals & Biotechnology	0.17%

Show 21 moreShow fewer

Short positions 1

Holding	Sector / type	% of fund
Net Current Assets	–	-0.14%

Debt, money market and cash 2

Holding	Sector / type	% of fund
Triparty Repo	–	2.81%
Cash Margin - CCIL	–	0.02%

From the fund house's monthly portfolio (mf.nipponindiaim.com), as on 30 Sept 2026. Percentages are of the fund's net assets; short positions are negative. Published about ten days after each month ends.

Risk

Volatility12.3%yearly, from daily NAVs

Worst fall-17.23%31 Aug 2021 → 30 Jun 2022

RiskometerVery HighVery High

Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 31 May 2016).

Fund details

Fund size (average AUM, July - September 2026)	₹9,272 cr across all plans · this plan ₹6,534 cr
Fund house	Nippon India Mutual Fund
Category	Equity · Sectoral / Thematic
Plan	Regular
Option	Growth
Exit load	1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Minimum investment	₹5,000 · additional ₹1,000
Scheme code (AMFI)	102431
ISIN	INF204K01968
NAV date	5 Nov 2026

Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.

Other plans of this fund

Plan	NAV	1 year
Direct · Growth	₹640.9532	+10.92%
Direct · IDCW	₹175.4153	+2.81%
Direct · IDCW	₹640.9532	+10.92%
Regular · IDCW	₹568.9138	+9.96%
Regular · IDCW	₹122.8536	+1.88%

Top Sectoral / Thematic funds (regular plans)

Fund	1 year	3 years (a year)
Nippon India Taiwan Equity Fund	+47.19%	+43.51%
HDFC Defence Fund	+17.69%	+34.19%
HDFC Pharma and Healthcare Fund	+24.81%	+29.79%
SBI HEALTHCARE OPPORTUNITIES FUND	+19.79%	+24.25%
HDFC Transportation and Logistics Fund	+7.84%	+24.00%
UTI - Healthcare Fund	+16.17%	+23.25%
Mirae Asset Healthcare Fund	+20.29%	+22.85%
BANK OF INDIA MANUFACTURING & INFRASTRUCTURE FUND	+16.15%	+22.19%
Nippon India Pharma Fund	+9.96%	+17.96%

All Sectoral / Thematic funds ranked › · Compare with others ›

← All mutual funds

Information only, not investment advice.

What is the NAV of Nippon India Pharma Fund - Regular Plan - Growth today?

₹568.9138 as of 5 Nov 2026, from AMFI's official NAV data.

What are the returns of Nippon India Pharma Fund - Regular Plan - Growth?

1 year: 9.96%, 3 years: 17.96% a year, 5 years: 13.72% a year

How does Nippon India Pharma Fund rank in its category?

55 of 280 Sectoral / Thematic funds (regular plans, growth option) by 1-year return.

What is the difference between direct and regular plans?

Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.